WYETH-AYERST TO PAY AFFYMAX $57 MIL. IN DRUG DISCOVERY AGREEMENT
Executive Summary
WYETH-AYERST TO PAY AFFYMAX $57 MIL. IN DRUG DISCOVERY AGREEMENT in exchange for worldwide rights to any potential products developed under the five-year collaboration. Announced Feb. 28, the agreement calls for Wyeth-Ayerst to make $47 mil. in R&D payments to Affymax over five years to fund a drug discovery program at Affymax' Palo Alto, Calif. facility. Wyeth will also purchase $10 mil. of Affymax common stock at $20 per share, or approximately 500,000 shares, giving the company about a 3% equity stake. Affymax will have 15.9 mil. shares outstanding post- transaction.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth